Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALT Covid-19: Inhaled ciclesonide for hospitalized Covid-19 pneumonia
2020-001928-34Phase 2Terminated
- Sponsor
- Capio S:t Görans Sjukhus
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ciclesonide in coronavirus pneumonia (2 arms), sponsored by Capio S:t Görans Sjukhus. Primary endpoint: Days with oxygen therapy within 30 days. Started Apr 2020; status: terminated.
02
Drugs
ciclesonide
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001928-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001928-34.